| 3.35 -0.01 (-0.3%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.07 | 1-year : | 4.76 |
| Resists | First : | 3.49 | Second : | 4.07 |
| Pivot price | 2.99  |
|||
| Supports | First : | 2.83 | Second : | 2.43 |
| MAs | MA(5) : | 3.31 |
MA(20) : | 2.95 |
| MA(100) : | 3.69  |
MA(250) : | 3.8 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 91.1 |
D(3) : | 93.5 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 4.82 | Low : | 2.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XFOR ] has closed below upper band by 21.2%. Bollinger Bands are 62.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.42 | 3.42 - 3.44 |
| Low: | 3.15 - 3.17 | 3.17 - 3.19 |
| Close: | 3.32 - 3.35 | 3.35 - 3.38 |
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Thu, 29 Oct 2026
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance
Thu, 29 Oct 2026
XFOR: Mavorixafor targets a 15,000–30,000-patient PCN market, with pivotal data due Q1 2028 - TradingView
Thu, 29 Oct 2026
A second mavorixafor study is planned for Q1 2027 at X4 Pharmaceuticals (XFOR). - Stock Titan
Fri, 23 Oct 2026
X4 Pharmaceuticals, Inc. Estimates – NASDAQ:XFOR - TradingView
Fri, 23 Oct 2026
X4 Pharmaceuticals (NasdaqCM:XFOR) Stock Forecast & Analyst Predictions - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 103.8 (%) |
| Shares Short | 7,590 (K) |
| Shares Short P.Month | 7,190 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | -186.2 % |
| Return on Assets (ttm) | -28.2 % |
| Return on Equity (ttm) | -113.1 % |
| Qtrly Rev. Growth | 346.2 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -84 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | 167.5 |
| PEG Ratio | 0 |
| Price to Book value | 2.06 |
| Price to Sales | 20.95 |
| Price to Cash Flow | -3.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|